Latanoprost (0.01% w/v) is an ophthalmic solution belonging to the prostaglandin analog class, widely used in the management of elevated intraocular pressure associated with conditions such as glaucoma and ocular hypertension. Its primary mechanism involves enhancing the outflow of aqueous humor through the uveoscleral pathway, thereby reducing pressure within the eye and helping to preserve optic nerve function. By lowering intraocular pressure effectively, latanoprost plays a crucial role in preventing progressive vision loss and maintaining long‑term ocular health. The formulation is designed for topical application, ensuring direct action at the site of concern while minimizing systemic involvement. Clinically, latanoprost is valued for its once‑daily dosing convenience, which supports patient adherence and consistent therapeutic outcomes. It is often considered a first‑line agent due to its efficacy, tolerability, and ability to provide sustained pressure reduction. Beyond its therapeutic role, latanoprost contributes significantly to improving quality of life for individuals at risk of glaucoma‑related complications, offering reassurance of controlled eye pressure and protection of visual function. Overall, latanoprost 0.01% w/v stands as a reliable and effective ophthalmic preparation, combining targeted pharmacological action with practical ease of use to safeguard vision and promote ocular well‑being.